Preliminary results suggested that EGFR wild-type lung cancer cell H1650 and EGFR mutant lung cancer H1975 cells showed poor sensitivity to icotinib with IC50 values of >50 μM, and 3l exhibited stronger killing effects on the lung cancer cell lines than icotinib did. This evidence concerns the gene EGFR and lung carcinoma.